A new systematic review and meta-analysis showed a small but significant reduction in subjective pain scores for cannabinoid treatment compared to placebo in patients experiencing acute pain. No increase in serious adverse events suggested the safety of using cannabinoids to treat acute pain, according to the study published in CannabisRead
A new study shows that cannabis may be helpful to address the effects of post-traumatic stress disorder (PTSD). According to health survey data collected by Statistics Canada from more than 24,000 Canadians, researchers from the BC Centre on Substance Use (BCCSU) and University of British Columbia (UBC) found that peopleRead
In this summary-scientific review from Mayo Clinical Proceedings, the researchers provide an overview of the scientific work on cannabidiol and hemp oil and the distinction between marijuana, hemp, and the different components of CBD and hemp oil products. They summarize the current legal status of CBD and hemp oils inRead
The FDA announced that it will host further cannabidiol hearing on the regulatory structure of CBD products in the early fall. The news was embedded in a press release regarding a warning issued to a CBD maker CuraLeaf for making unfounded claims to treat cancer, Alzheimer’s disease, opioid withdrawal, painRead
Medicinal cannabis oil containing both cannabidiol (CBD) and a small amount of THC can reduce or end seizures in children with severe, drug-resistant epilepsy, a study by the University of Saskatchewan (USask), Canada has found. Children with severe drug-resistant epilepsy also experienced improvements in their quality of life after takingRead
The disabling condition of obsessive-compulsive disorder (OCD) affects about 2–3% of people worldwide. Evidence suggests that abnormalities in cortico-striatal-thalamic-cortical circuitry and specific gene variants contribute to the pathogenesis of the disorder. This latest study, published in Cannabis and Cannabinoid Research, suggests that the endocannabinoid system (ECS) plays a role in OCD symptomsRead
New Rochelle, NY, May 7, 2019—Cannabis and Cannabinoid Research (CCR) is extremely excited to announce that the International Cannabinoid Research Society (ICRS) has named CCR its Official Journal. The ICRS is a foremost international society spearheading scientific research in all fields of cannabinoids, ranging from biochemical, chemical, and physiological studiesRead
Patients are aware that medical cannabis and cannabinoid derivatives are available to treat pain and symptoms. However, the medical literature to guide palliative medicine physicians in recommending cannabis and cannabinoid use is not yet well developed. The Journal of Palliative Care, David Casarett, MD, Guest Editor and Chief of Palliative CareRead
Neurotransmitters and neurochemicals can act on lymphocytes by binding to receptors expressed by lymphocytes. This review describes lymphocyte expression of receptors for a selection of neurotransmitters and neurochemicals, the anatomical locations where lymphocytes can interact with neurotransmitters, and the effects of the neurotransmitters on lymphocyte function. Implications for health andRead
As more states legalize medical cannabis, clinicians are seeking more information on how it may affect elderly populations for chronic conditions associated with aging. In this study, published in the journal Neurology, researchers evaluated medical cannabis’ (MC) efficacy and adverse effects (AE) in patients 75 years of age or older.Read
Weekly round-up, access to thought leaders, and articles to help you improve health outcomes and the success of your practice.
